These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 9723272)

  • 21. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a Neoral-equivalent cyclosporine formulation, using a dose-adjusted method.
    First MR; Weiskittel P; Shah M; Peddi VR; Canafax D; Schroeder TJ
    Transplant Proc; 1998 Dec; 30(8):3955-7. PubMed ID: 9865260
    [No Abstract]   [Full Text] [Related]  

  • 22. Optimization of cyclosporine therapy in kidney transplantation.
    Remuzzi G; Perico N; Gaspari F
    Transplant Proc; 1998 Aug; 30(5):1673-6. PubMed ID: 9723238
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparative bioavailability of Neoral and Sandimmune in cardiac transplant recipients over 1 year.
    Cooney GF; Jeevanandam V; Choudhury S; Feutren G; Mueller EA; Eisen HJ
    Transplant Proc; 1998 Aug; 30(5):1892-4. PubMed ID: 9723323
    [No Abstract]   [Full Text] [Related]  

  • 24. Renal recipients of haploidentical living donors treated with Neoral or conventional cyclosporine: a comparative follow-up of 3 years.
    Gracida C; Melchor JL
    Transplant Proc; 1998 Aug; 30(5):1742-3. PubMed ID: 9723262
    [No Abstract]   [Full Text] [Related]  

  • 25. Cyclosporine A: peak or trough level monitoring in renal transplant recipients?
    Wacke R; Drewelow B; Kundt G; Hehl EM; Bast R; Seiter H
    Transplant Proc; 2001; 33(7-8):3122-3. PubMed ID: 11750342
    [No Abstract]   [Full Text] [Related]  

  • 26. High performance liquid chromatography cyclosporine monitoring: a predictor of renal graft outcome.
    Cicciarelli J; Avila D; Iwaki Y; Sather H; Mendez R
    Transplant Proc; 1998 Aug; 30(5):1683-4. PubMed ID: 9723243
    [No Abstract]   [Full Text] [Related]  

  • 27. Estimation of mean relative bioavailability of cyclosporine Sandimmune and Neoral using NONMEM in renal transplant recipients.
    Lee KL; Lee KT; Chung HM; Lin YP
    Transplant Proc; 1998 Nov; 30(7):3526-9. PubMed ID: 9838545
    [No Abstract]   [Full Text] [Related]  

  • 28. Safety and tolerability of Sandimmun Neoral vs Sandimmun in de novo renal transplant patients after 24 months' treatment. German Neoral Study Group.
    Buchholz B; Korn A
    Transplant Proc; 1996 Aug; 28(4):2187-8. PubMed ID: 8769195
    [No Abstract]   [Full Text] [Related]  

  • 29. Neoral versus Sandimmune in kidney transplantation.
    Tisone G; Orlando G; Mercadante E; Vennarecci G; Pisani F; Buonomo O; Negrini S; Casciani CU
    Transplant Proc; 1998 Aug; 30(5):1749-50. PubMed ID: 9723265
    [No Abstract]   [Full Text] [Related]  

  • 30. Neoral (cyclosporine) C2 monitoring in renal transplant recipients: a single-center experience in Asia.
    Wong HS; Morad Z
    Transplant Proc; 2003 Feb; 35(1):230-1. PubMed ID: 12591376
    [No Abstract]   [Full Text] [Related]  

  • 31. UK multicentre study to assess the safety and tolerability of Neoral in stable renal transplant patients. U.K. Neoral Study Group.
    Moore RH
    Transplant Proc; 1996 Aug; 28(4):2202-3. PubMed ID: 8769200
    [No Abstract]   [Full Text] [Related]  

  • 32. Abbreviating area under the curves further: a practical approach to monitoring extended pharmacokinetics with Neoral.
    Sindhi R; Shah J; Foley L; Bucsis J; Kyryliuk T; Baliga PK; Rajagopalan PR
    Transplant Proc; 1998 Jun; 30(4):1197-8. PubMed ID: 9636485
    [No Abstract]   [Full Text] [Related]  

  • 33. Cyclosporine pharmacokinetic profiles in stable renal allograft recipients converting from Sandimmun to Neoral.
    Vathsala A; Lee WT; Jacob E; Woo KT
    Transplant Proc; 1996 Jun; 28(3):1324-6. PubMed ID: 8658678
    [No Abstract]   [Full Text] [Related]  

  • 34. Area under the curve of Neoral and chronic use of mycophenolate mofetil.
    Rial M; Guardia O; Greco G; Argento J; Casadei D
    Transplant Proc; 1998 Jun; 30(4):1195-6. PubMed ID: 9636484
    [No Abstract]   [Full Text] [Related]  

  • 35. Abbreviated cyclosporine pharmacokinetic profiling in clinical renal transplantation: from principles to practice.
    Vathsala A; Lu YM
    Transplant Proc; 2001; 33(7-8):3137-9. PubMed ID: 11750348
    [No Abstract]   [Full Text] [Related]  

  • 36. Limited sampling strategy to estimate exposure to cyclosporine A in renal allograft recipients treated with Sandimmune-Neoral.
    Serafinowicz A; Gaciong Z; Baçzkowska T; Rell K; Lao M; Wałaszewski J
    Transplant Proc; 1996 Dec; 28(6):3138-9. PubMed ID: 8962216
    [No Abstract]   [Full Text] [Related]  

  • 37. A retrospective analysis of Neoral C2 monitoring in Chinese renal transplantation recipients.
    Tan J; Tang X
    Transplant Proc; 2003 Feb; 35(1):232-3. PubMed ID: 12591377
    [No Abstract]   [Full Text] [Related]  

  • 38. C0/C2 cyclosporine levels monitoring in renal transplantation.
    Santana A; Guerra J; Milhomens C; Neves F; Prata MM
    Transplant Proc; 2003 May; 35(3):1072-3. PubMed ID: 12947862
    [No Abstract]   [Full Text] [Related]  

  • 39. Conversion from Sandimmune to Neoral in renal transplant recipients: two-year experience.
    Wilczek HE; Akesson P; Warholm C
    Transplant Proc; 1998 Aug; 30(5):1753-5. PubMed ID: 9723267
    [No Abstract]   [Full Text] [Related]  

  • 40. Conversion from Sandimmune to Neoral in renal transplant: functional histopathological, and pharmacokinetic changes.
    Roessler E; Herrera S; Espinoza M; Ayala A; Reynolds E; González F; Espinoza O; Undurraga A; Muñoz R; Arcos O; Galaz G
    Transplant Proc; 1998 Aug; 30(5):1756-7. PubMed ID: 9723268
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.